AIM ImmunoTech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AIM American 2834 https://aimimmuno.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc

AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy - Oct 6th, 2021 11:25 am
AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer - Oct 4th, 2021 1:20 pm
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses - Sep 30th, 2021 10:00 am
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19 - Sep 28th, 2021 1:20 pm
AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses - Sep 27th, 2021 1:20 pm
AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction - Sep 21st, 2021 11:25 am
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen - Sep 20th, 2021 1:15 pm
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction - Sep 8th, 2021 1:00 pm
AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) - Aug 25th, 2021 1:00 pm
AIM ImmunoTech Provides Second Quarter 2021 Business Update - Aug 17th, 2021 1:00 pm
AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc. - Aug 16th, 2021 11:25 am
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy - Jul 9th, 2021 11:25 am
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET - Jul 6th, 2021 6:15 pm
AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen - Jun 21st, 2021 1:00 pm
AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2 - Jun 14th, 2021 11:15 am
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen - May 27th, 2021 12:45 pm
AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial - May 26th, 2021 1:15 pm
AIM ImmunoTech Provides First Quarter 2021 Business Update - May 18th, 2021 11:30 am
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo - May 3rd, 2021 11:30 am
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases - Apr 27th, 2021 11:15 am